RCM
PGNX

Rotella Capital Management’s Progenics Pharmaceuticals Inc PGNX Stock Holding History

Rotella Capital Management’s Portfolio PGNX Stock Details PGNX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q4 		– Sell
-16,300
Closed -$93K – 628
2015
Q3 		$93K Buy
16,300
+4,242
+35% +$32.6K 0.03% 437
2015
Q2 		$90K Buy
+12,058
New +$73K 0.07% 293
2015
Q1 		– Sell
-36,473
Closed -$276K – 640
2014
Q4 		$276K Buy
+36,473
New +$218K 0.24% 84

Other funds holding PGNX

Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
BC
Broadfin Capital New York $747M AUM 100.56% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Tudor Investment Corp
Tudor Investment Corp Stamford, Connecticut $53.9B AUM 29.12% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
RA
Royce & Associates New York $10.1B AUM 42.88% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Rotella Capital Management's PGNX Position: Q4 2015 in Review

Rotella Capital Management sold out of Progenics Pharmaceuticals Inc (PGNX) in Q4 2015, closing a stake of 16,300 shares — an estimated $93K sold.

Rotella Capital Management first reported a position in PGNX in Q4 2014 and held it in 3 quarters. The position peaked at $276K in Q4 2014. 121 funds tracked by Wall St. Rank hold PGNX as of Q4 2015.

  • Rotella Capital Management reported no remaining Progenics Pharmaceuticals Inc position as of Q4 2015 after selling out during the quarter.
  • Rotella Capital Management sold 16,300 Progenics Pharmaceuticals Inc shares in Q4 2015, an estimated $93K.
  • Rotella Capital Management first reported a position in Progenics Pharmaceuticals Inc in Q4 2014 and held it in 3 quarters.
  • Rotella Capital Management's Progenics Pharmaceuticals Inc position peaked at $276K in Q4 2014.
  • 121 funds tracked by Wall St. Rank held Progenics Pharmaceuticals Inc as of Q4 2015.

Based on Rotella Capital Management's 13F filing for Q4 2015, filed 9 Feb 2016.